Literature DB >> 22367296

Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.

John C Cheville1, Christine M Lohse, William R Sukov, Robert Houston Thompson, Bradley C Leibovich.   

Abstract

It has been reported that Fuhrman grading is not appropriate for chromophobe renal cell carcinoma (RCC). The objective of this study was to determine whether nucleolar grading and the recently described chromophobe RCC grading system by Paner and colleagues provide prognostic information. Pathologic features of 185 patients with chromophobe RCC treated surgically between 1970 and 2006 were reviewed, including nucleolar grade, chromophobe RCC grade, the 2010 TNM groupings, sarcomatoid differentiation, and coagulative tumor necrosis. Cancer-specific (CS) survival was estimated using the Kaplan-Meier method, and associations with CS survival were evaluated using Cox proportional hazard regression models. Twenty-three patients died from RCC at a mean of 3.0 years after surgery (median 1.3; range 0 to 16) with estimated CS rates (95% confidence interval) of 89% (84 to 94), 86% (81 to 92), and 85% (78 to 91) at 5, 10, and 15 years after surgery. Univariate associations with CS survival included the 2010 TNM stage groupings, sarcomatoid differentiation, coagulative tumor necrosis, chromophobe RCC grade, and nucleolar grade (all P<0.001). These last 4 features remained significantly associated with CS survival after adjusting for the 2010 TNM stage groupings. When the analysis was restricted to the 155 patients with nonsarcomatoid TNM stage groupings I and II chromophobe RCC, only stage grouping (I vs. II) was significantly associated with CS survival (P=0.03). Although the chromophobe RCC grading system described by Paner and colleagues and nucleolar grade are associated with CS survival in chromophobe RCC, they add no additional prognostic information once TNM stage and sarcomatoid differentiation are assessed.

Entities:  

Mesh:

Year:  2012        PMID: 22367296     DOI: 10.1097/PAS.0b013e3182496895

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  21 in total

1.  Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.

Authors:  Serge Ginzburg; Robert Uzzo; Tahseen Al-Saleem; Essel Dulaimi; John Walton; Anthony Corcoran; Elizabeth Plimack; Reza Mehrazin; Jeffrey Tomaszewski; Rosalia Viterbo; David Y T Chen; Richard Greenberg; Marc Smaldone; Alexander Kutikov
Journal:  J Urol       Date:  2013-07-27       Impact factor: 7.450

2.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

3.  Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors.

Authors:  Boyd R Viers; R Houston Thompson; Christine M Lohse; John C Cheville; Bradley C Leibovich; Stephen A Boorjian; Matthew K Tollefson
Journal:  World J Urol       Date:  2016-04-06       Impact factor: 4.226

Review 4.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

Review 5.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

6.  Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.

Authors:  Yasser Ged; Ying-Bei Chen; Andrea Knezevic; Jozefina Casuscelli; Almedina Redzematovic; Renzo G DiNatale; Maria I Carlo; Chung-Han Lee; Darren R Feldman; Sujata Patil; A Ari Hakimi; Paul Russo; Robert J Motzer; Martin H Voss
Journal:  Clin Genitourin Cancer       Date:  2019-04-01       Impact factor: 2.872

7.  [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].

Authors:  M May; R Zigeuner; A Aziz; L Cindolo; C Gilfrich; L Schips; O De Cobelli; B Rocco; C De Nunzio; A Tubaro; I Coman; B Feciche; M Truss; B Hoschke; O Dalpiaz; A Stoltze; F Fenske; H-M Fritsche; T Chromecki; S Lebentrau; R S Figenshau; K Madison; M Sánchez-Chapado; M Del Carmen Santiago Martin; L Salzano; G Lotrecchiano; S Joniau; R Waidelich; C G Stief; S Brookman-May
Journal:  Urologe A       Date:  2014-02       Impact factor: 0.639

Review 8.  Biomarkers in renal cancer.

Authors:  Holger Moch; John Srigley; Brett Delahunt; Rodolfo Montironi; Lars Egevad; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

9.  Chromophobe renal cell carcinoma--chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases.

Authors:  Maris Sperga; Petr Martinek; Tomas Vanecek; Petr Grossmann; Kevin Bauleth; Delia Perez-Montiel; Isabel Alvarado-Cabrero; Kristine Nevidovska; Vilnis Lietuvietis; Milan Hora; Michal Michal; Fredrik Petersson; Naoto Kuroda; Saul Suster; Jindrich Branzovsky; Ondrej Hes
Journal:  Virchows Arch       Date:  2013-08-03       Impact factor: 4.064

10.  Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.

Authors:  Pierre Bigot; Jean-Christophe Bernhard; Vincent Flamand; Inderbir Gill; Grégory Verhoest; Jean Baptiste Beauval; François Xavier Nouhaud; Evren Suer; Guillaume Ploussard; Jean François Hetet; Jérôme Rigaud; Eduard Baco; Stéphane Larré; Philippe Sebe; Nicolas Koutlidis; Aurélien Descazeaud; Masatoshi Eto; Arnaud Doerfler; Morgan Roupret; Nam Son Vuong; Boris Reix; Toru Matsugasumi; Adnan El Bakri; Laurence Albiges; Michel Soulié; Jean-Jacques Patard; Arnaud Méjean; Karim Bensalah
Journal:  Urol Oncol       Date:  2016-09-28       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.